Abbott Laboratories $ABT Stock Sold by LaFleur & Godfrey LLC

Key Points

• LaFleur & Godfrey LLC reduced its Abbott Laboratories stake by 14.3% in the third quarter, selling 11,070 shares and retaining 66,136 shares valued at approximately $6.5 million.
• Abbott reported quarterly revenue of $13.01 billion, up 14.5% year over year, while adjusted earnings of $1.42 per share matched analysts’ expectations.
• ABT offers an annualized $2.52 dividend yielding about 2.5%, while analysts maintain a “Moderate Buy” consensus rating with an average price target of $118.32.

LaFleur & Godfrey LLC trimmed its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 14.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 66,136 shares of the healthcare product maker's stock after selling 11,070 shares during the quarter. LaFleur & Godfrey LLC's holdings in Abbott Laboratories were worth $6,536,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after acquiring an additional 6,769,518 shares during the period. State Street Corp raised its holdings in Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after purchasing an additional 1,350,766 shares in the last quarter. Bank of America Corp DE acquired a new stake in Abbott Laboratories in the second quarter worth approximately $1,603,607,000. Deutsche Bank AG lifted its position in Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock worth $1,515,963,000 after purchasing an additional 2,614,965 shares during the period. Finally, Legal & General Group Plc bought a new position in Abbott Laboratories during the 2nd quarter valued at $1,082,524,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Down 0.4%

ABT stock opened at $102.66 on Thursday. The firm has a market cap of $177.64 billion, a PE ratio of 38.31, a P/E/G ratio of 1.82 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a 50 day simple moving average of $104.72 and a 200 day simple moving average of $102.26.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The company had revenue of $13.01 billion for the quarter, compared to analysts' expectations of $12.99 billion. During the same quarter in the prior year, the company earned $1.30 earnings per share. The firm's revenue was up 14.5% on a year-over-year basis. Equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories's payout ratio is 94.03%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ABT. JPMorgan Chase & Co. lowered their price target on Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating on the stock in a research report on Thursday, October 22nd. Royal Bank Of Canada cut their price objective on Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Thursday, October 22nd. Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. Robert W. Baird lifted their target price on Abbott Laboratories from $121.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, October 22nd. Finally, BTIG Research dropped their price target on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating on the stock in a research report on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average target price of $118.32.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott launched a next-generation Oncodetect test designed to detect residual cancer disease, expanding its diagnostics portfolio and potentially supporting longer-term growth in oncology testing. Abbott Launches Next-Generation Oncodetect Test
• Positive Sentiment: The planned spin-off of Abbott’s Nutrition segment, which generates approximately $8.5 billion in annual sales, could allow the remaining company and the new standalone business to pursue more focused strategies. Abbott has appointed Daniel Salvadori to lead the future Nutrition company. What Could Abbott Laboratories Spin Off Mean for Its Future Growth?
• Positive Sentiment: Abbott received approximately $23.9 million in net ETF buying, indicating some continued institutional demand for ABT shares despite recent volatility. Abbott Sees $23.9 Million in Net ETF Buying
• Neutral Sentiment: Abbott is included in coverage of Europe’s medical foods market, which is projected to grow from $6.5 billion in 2026 to $7.9 billion by 2033. The outlook highlights a long-term opportunity for Abbott’s specialized nutrition business, though it does not represent new company-specific revenue. Europe Medical Foods Market Strategic Outlook
• Negative Sentiment: Argus Research downgraded Abbott from “Buy” to “Hold,” reportedly citing a guidance cut. The change removes a bullish rating catalyst and reinforces investor concerns about near-term demand and earnings visibility. Abbott Downgraded at Argus on Guidance Cut
• Negative Sentiment: Higher interest-rate expectations are creating pressure on richly valued quality-growth stocks such as Abbott, as elevated rates can reduce the value investors assign to future earnings. Demand headwinds and litigation risks are also cited as concerns. Abbott Demand Headwinds and Litigation Risks

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.